Drug Trial Radar · NCT05087069
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects
Last checked: Nov 19, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Oct 8, 2021
Primary completion
Apr 8, 2022
Study completion Jan 12, 2023
Sponsor
- Lead sponsor
- BioVersys SASIndustry
- Sponsor type
- Industry
- Collaborators
- Nuvisan GmbH
- First posted
- Oct 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety and tolerability and Pharmacokinetics of multiple doses of BV100 in healthy volunteers
Conditions
- Healthy Volunteers
Interventions
BV100Drug
Rifabutin for Infusion
PlaceboDrug
Saline intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the safety and tolerability of increasing multiple intravenous doses of BV100Time frame: 21 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuvisan GmbH
Neu-Ulm, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.